Biomedical Engineering Reference
In-Depth Information
22. Cortez, D., Kadlec, L., and Pendergast, A. M. (1995) Structural and
signaling requirements for BCR-ABL-mediated transformation and
inhibition of apoptosis,
, 15, pp. 5531-5541.
23. Dai, Z., Quackenbush, R. C., Courtney, K. D., Grove, M., Cortez, D., Reuther,
G. W., and Pendergast, A. M. (1998) Oncogenic ABL and SRC tyrosine
kinases elicit the ubiquitin-dependent degradation of target proteins
through a Ras-independent pathway,
Mol. Cell. Biol.
, 12, pp. 1415-1424.
24. Goldman, J. M. (2007) How I treat chronic myeloid leukemia in the
imatinib era,
Genes. Dev.
, 110, pp. 2828-2837.
25. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C.,
Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R.,
Zoellner, U., Talpaz, M., Druker, B., Goldman, J., O'Brien, S. G., Russell,
N., Fischer, T., Ottmann, O., Cony-Makhoul, P., Facon, T., Stone, R.,
Miller, C., Tallman, M., Brown, R., Schuster, M., Loughran, T., Gratwohl,
A., Mandelli, F., Saglio, G., Lazzarino, M., Russo, D., Baccarani, M., and
Morra, E. (2002) Hematologic and cytogenetic responses to imatinib
mesylate in chronic myelogenous leukemia,
Blood
N. Engl. J. Med.
, 346, pp.
645-652.
26. O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M.,
Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T.,
Lechner, K., Nielsen, J. L., Rousselot, P., Reiffers, J., Saglio, G., Shepherd,
J., Simonsson, B., Gratwohl, A., Goldman, J. M., Kantarjian, H., Taylor,
K., Verhoef, G., Bolton, A. E., Capdeville, R., and Druker, B. J. (2003)
Imatinib compared with interferon and low-dose cytarabine for newly
diagnosed chronic-phase chronic myeloid leukemia,
N. Engl. J. Med.
,
348, pp. 994-1004.
27. O'Brien, S., Guilhot, F., Goldman, J., Hochhaus, A., Hughes, T., Radich, J.,
Rudoltz, M., Filian, J., Gathmann, I., Druker, B., and Larson, R. (2008)
International randomized study of interferon versus STI571 (IRIS)
7-year ollow-up: sustained survival, low rate of transformation and
increased rate of major molecular response (MMR) in patients (pts)
with newly diagnosed chronic myeloid leukemia in chronic phase
(CMLCP) treated with imatinib (IM),
Blood (ASH Annual Meeting
, 112, Abstract 186.
28. Deininger, M., O'Brien, G., and Guilhot, F. (2009) International
Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up:
sustained survival and low risk for progression or events in patients
with newly diagnosed chronic myeloid leukemia in chronic phase
(CML-CP) treated with imatinib,
Abstracts)
Blood (ASH Annual Meeting Abstracts)
,
114, abstract 1126.
